Profil:
Sopharma ADSOPHARMA AD (102/2024) Sales revenues for August 2024
Report no 102/2024
Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
Sofia, Bulgaria, September 20, 2024 - According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), "Sopharma" AD (SFA: "Bulgarian Stock Exchange" AD, SPH: Warsaw Stock Exchange) notifies, that for August 2024 the Company recorded a decrease in sales of 3% compared to the same month of the previous year, incl. 30% increase in domestic sales and 16% decrease in export sales.
For the period from the beginning of 2024, the Company recorded a decrease in sales of 7%, incl. 8% increase of domestic sales and 15% decrease in export sales.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz